Page 3 - J Amp News Today

The healthcare giant said Thursday that it will replace the well-known signature script it has used since 1887 with a modern look that reflects its sharpened focus on pharmaceuticals and medical devices.

According to a proposed class action on Wednesday filed in Pensacola, Florida, federal court, the companies knew or should have known by 2018 that their marketing claims about products containing phenylephrine were false and misleading. That year was when new FDA guidance for evaluating symptoms related to nasal congestion demonstrated that earlier data about phenylephrines effectiveness could no longer be relied upon, the complaint said.

A medical researcher has asked a court to throw out a lawsuit that Johnson & Johnson filed against her over her 2019 study on the links between cosmetic talc products and cancer, saying that her research is sound and protected by free speech rights. Dr. Jacqueline Moline, who has served as a plaintiffs' expert in more than 200 cases alleging that J&J talc products caused patients to develop cancer, said in a Friday court filing in federal court in Trenton, New Jersey, that the lawsu...

Adding chemotherapy cuts the risk of disease progression or death 38%, trial shows

Johnson & Johnson's Rybrevant became the first medication for a particular subset of non-small cell lung cancer (NSCLC) in 2021.

Johnson & Johnson's Rybrevant became the first medication for a particular subset of non-small cell lung cancer (NSCLC) in 2021.

The bearish investors made $14.8 billion on aggregate last month after shedding $16.5 billion in July

The Health Justice Initiative on Tuesday labelled the contracts the government signed with pharmaceutical manufacturers and suppliers during the height of the Covid-19 pandemic as one-sided and unethical.

The contracts that South Africa signed to procure Covid-19 vaccines showed the country was forced to overpay for vaccines and the terms and conditions were overwhelmingly one-sided and favoured multinational corporations.

Johnson & Johnson and Lupin will supply their versions of the tuberculosis drug bedaquiline at a significantly cheaper price in low- and middle-income countries, according to the Stop TB Partnership. The new prices, $130 for J&J and $194 for Lupin for a six-month course of treatment, represent a 55% and 33% reduction, respectively. Bedaquiline is a key part of recommended treatment regimens for drug-resistant TB infections, and this price reduction will help broaden access to the life-sa...